Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493728 | 1.00 | ALDH1A1 (0.69) | ALDH1A1KMT2ALMNAMAPTGAA | |
| Hydrochloric Acid SCHEMBL30255520 | 0.98 | ALDH1A1 (0.68) | ALDH1A1KMT2ALMNAMAPTGAA | |
| Hydrochloric Acid SCHEMBL4003615 | 0.98 | ALDH1A1 (0.68) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL6499951 | 0.94 | ALDH1A1 (0.63) | ALDH1A1KMT2ALMNAMAPTGAA | |
| Hydrochloric Acid SCHEMBL3201233 | 0.93 | ALDH1A1 (0.61) | ALDH1A1KMT2ALMNAMAPTGAA | |
| Methylpiperazine SCHEMBL5742882 | 0.89 | ALDH1A1 (0.62) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL14464189 | 0.89 | ALDH1A1 (0.79) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL27747369 | 0.88 | MAPT (0.58) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL26655535 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KMT2ALMNAMAPTGAA | |
| Tert-Butyl Formate SCHEMBL28761559 | 0.87 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-117720516-A | Advantageous crystalline forms of selective BRD9 degrading agents | C4医药公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2023039208-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2005051933-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF 4-(4-BENZYLOXY-CARBONYLAMINO-2-FLUOROPHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, A KEY INTERMEDIATE FOR OXAZOLIDINONE ANTIMICROBIALS AND COMPOUNDS PREPARED THEREBY | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-09 | — | — | WO | claimed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-1401834-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004018439-A1 | NOVEL ANTIBACTERIAL AGENTS | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003002560-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2003-01-09 | — | — | WO | disclosed |
| EP-0640077-B1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | UPJOHN CO (US) | 2002-06-26 | — | — | EP | disclosed |
| CN-1044236-C | Oxazolidinone antimicrobials containing substituted diazine moieties | PHARMACIA UPJOHN CO (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5700799-A | MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5547950-A | FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | THE UPJOHN COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| WO-1993023384-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | ALDH1A1 959/4885KMT2A 440/4885LMNA 2978/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | ALDH1A1 1225/4885KMT2A 396/4885LMNA 2666/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | ALDH1A1 1790/4885KMT2A 2021/4885LMNA 1900/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885LMNA 2707/4885 |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | ALDH1A1 1877/4885KMT2A 2954/4885LMNA 1848/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | ALDH1A1 959/4885KMT2A 440/4885LMNA 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.